Literature DB >> 2492835

Myelomonocytic myeloma cell line (LB 84-1).

B G Durie1, T M Grogan, C Spier, E Vela, V Baum, M A Rodriquez, Y Frutiger.   

Abstract

A human cell line (LB 84-1) has been established from the bone marrow of a patient with Bence-Jones myeloma. Coexpression of plasma cell (Leu[CD38]) and myelomonocytic antigens (Leu MI[CD15], Leu M5 [CD11c], MY7 [CD13] plus butyrate and chloracetate esterase) proved to be an unusual but sustained feature of this cell line. The plasma cell phenotype with multinuclearity was retained. Shared major chromosomal abnormalities (del [5] [p14], t[5;?] [q35;?], del [6] [q21], and del 7[q32]) between the direct and cell line karyotypes affirmed the LB 84-1 cell as being derived from the original patient myeloma clone. The mechanisms potentially responsible for the aberrant coexpressed phenotype are discussed. This myelomonocytic myeloma cell line will hopefully prove to be a valuable tool for the study of the genotypic and phenotypic evolution of human myeloma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492835

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.

Authors:  Ping Wu; Brian A Walker; Daniel Brewer; Walter M Gregory; John Ashcroft; Fiona M Ross; Graham H Jackson; Anthony J Child; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

3.  Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.

Authors:  N Kuribayashi; H Hata; H Matsuzaki; M Yoshida; T Sonoki; A Nagasaki; T Kimura; N Harada; K Takatsuki
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.